Psychedelics
Breaking News: Toms Shoes Founder Pledges $100 million for Psychedelic Research
Blake Mycoskie, founder of Toms Shoes, has pledged to give $100 million to support psychedelic research and access
The post Breaking News: Toms Shoes Founder…
Donation is believed to be the largest ever in the psychedelics space
Blake Mycoskie, founder of Toms Shoes, has pledged to give $100 million to support psychedelic research and access.
In an interview with MarketWatch, Mycoskie said the money will help fund research, support academic institutions studying psychedelic medicine, and nonprofits working to increase access for patients in need of psychedelic treatments.
In the interview, Mycoskie said his personal experience with psychedelic therapy in 2017 (ayahuasca) led to see the potential for healing, saying that psychedelics “cracked me open, and it connected me more to my faith in God, made me feel that we were all connected and everything was fine and perfect…I came back just feeling like, wow, that was more powerful than any therapy I’d ever done.”
And as for the donation, $100 million works out to approx a quarter of Mycoskie’s net worth — what many are calling the most generous donation to psychedelics ever. Blake Mycoskie told MarketWatch: ”We really need to get this right, and we really need to have these foundations and nonprofits funded properly … I felt a real sense of urgency.”
Read the full interview here.
The post Breaking News: Toms Shoes Founder Pledges $100 million for Psychedelic Research appeared first on Microdose.
ayahuasca psychedelic psychedelic research therapy psychedelics fund research
-
Psychedelics1 week agoMindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week agoCompass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psychedelics1 week agoReunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psilocybin6 days agoThe Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Law & Regulation1 week agoGH Research advances depression therapies, burns cash